Test my supply
73%
Finnrick rating
#172 of 301 ranked vendors
93 of 110 classifiable tests passed
methodology · Purity focus
Finnrick analysis

Yimei's purity-focused record is strongest on GHK-Cu and Ipamorelin, where recent identity and high-purity results are consistent despite weak batch documentation. Retatrutide is higher-volume but volatile, and TB-500 carries the weakest signal; recent recovery across several peptides helps, but missing batch IDs limit confidence.

methodology →
vendor intelligence report
Vendor Intelligence Report: Yimei

Corporate records tie the Yimei-named UK layer to a dissolved company while Pepturion’s UK-facing site omits ordinary legal identifiers. The report maps the rebrand trail, Hong Kong contact signal, China-side supplier records, payment recourse gaps, and promo-code network.

26 pages6 risk factors assessed3 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.10
96%
15
2
Ipamorelin
$1.14
85%
8
3
Retatrutide
$1.28
84%
51
4
Tirzepatide
$0.56
81%
7
5
BPC-157
$1.42
63%
11
6
Tesamorelin
$3.69
55%
6
7
CJC-1295
$2.58
49%
7
8
TB-500
$3.03
42%
5
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%2 Mar 2026: 67%3 Mar 2026: 67%3 Mar 2026: 67%4 Mar 2026: 67%4 Mar 2026: 68%4 Mar 2026: 69%4 Mar 2026: 68%4 Mar 2026: 69%4 Mar 2026: 69%4 Mar 2026: 69%4 Mar 2026: 69%6 Mar 2026: 70%6 Mar 2026: 70%6 Mar 2026: 70%6 Mar 2026: 70%6 Mar 2026: 71%6 Mar 2026: 71%7 Mar 2026: 71%7 Mar 2026: 72%7 Mar 2026: 72%10 Mar 2026: 72%18 Mar 2026: 72%18 Mar 2026: 72%19 Mar 2026: 72%21 Mar 2026: 72%23 Apr 2026: 72%23 Apr 2026: 72%28 Apr 2026: 72%28 Apr 2026: 71%28 Apr 2026: 72%28 Apr 2026: 72%28 Apr 2026: 72%28 Apr 2026: 72%30 Apr 2026: 72%30 Apr 2026: 73%30 Apr 2026: 73%19 May 2026: 73%16 Jun 2026: 73%17 Jun 2026: 73%10 Jul 2026: 73%10 Aug 2026: current 73%67%71%73%Mar 26Aug 26
Test my supply
Yimei test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
10 Jul 2026Pass
Retatrutide
lab nameView COA
17 Jun 2026Pass
BPC-157
lab nameView COA
16 Jun 2026Pass
Retatrutide
lab nameView COA
19 May 2026Pass
Tirzepatide
lab nameView COA
30 Apr 2026Pass
Retatrutide
lab nameView COA
30 Apr 2026Pass
CJC-1295 (No DAC)
lab nameView COA
30 Apr 2026Pass
Ipamorelin
lab nameView COA
28 Apr 2026Fail
CJC-1295 (No DAC)
lab nameView COA
28 Apr 2026Pass
Tirzepatide
lab nameView COA
28 Apr 2026Pass
Retatrutide
lab nameView COA
1-10 of 110

About Yimei test results from Finnrick

Yimei is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 8 peptides and 110 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Yimei peptides in this dataset are CJC-1295 (7 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 110 recent tests.

Corrections
No corrections.
Test my supply